{"name":"Bioray Laboratories","slug":"bioray-laboratories","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiWkFVX3lxTE93aDREeE1MU2hRVkNWSUE2R09RZ1E2Y0d1TTM0ZWJuUUpUQjRzQi1LV0tSZkxEcEJXMGxha3JDb0d2ZHdYSERtUHBSUkJtNUdGdW9JMFRncDZSQQ?oc=5","date":"2025-04-02","type":"pipeline","source":"The Pharma Letter","summary":"Shanton Pharma - The Pharma Letter","headline":"Shanton Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0AFBVV95cUxQdTRXcDJUbzI2U195bTZrQ1NzTGhISDVFaXJsUzNpcUVBc0dJNTVRU2NveWNoU0N3bkpPY3ZvTGJvNHRScW81S1JmQWtnQ3dHNkRaUGVkRHZBblpBRmJYeHE1dnQ3UGRDS2FQZXZKUkZLa2JRQS1GZFFELXZXMDRQMzFYVkRLeGE2TUY5NVFfYUxxb2ZIQnVQeFVsTVN4QVE2Z2ZUVm1IbmtTNlRGSXd1cjlfd194aUpYZ2RLQm00WS1hbFhsR3RuVUJIZ05udW9K?oc=5","date":"2025-02-11","type":"trial","source":"BioPharma APAC","summary":"China's BioRay Secures NMPA Nod for Clinical Trials of BR111, a First-in-Class Anti-ROR1 ADC - BioPharma APAC","headline":"China's BioRay Secures NMPA Nod for Clinical Trials of BR111, a First-in-Class Anti-ROR1 ADC","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxOX3Q1M3hlZjB0QWJuVTZPNFpseUxwbU14bzJfanpzVG1rMGV6TlVIOFcwTUJYVTdoamF4ejVKeDlBSlZ1bXI2X2p4SFpGbVhQOURZYUJRVlFpRzZ2LS05cHZwbGQ3X3piT1Rmbl95MWM0RnVra1dhdUh2aGk5eWVkamFJSU9WaGJCU2w1YTlQdzBQREJHZWtRdGRxa3E2NG8?oc=5","date":"2024-11-30","type":"pipeline","source":"The Pharma Letter","summary":"UCB closes portfolio divestment and focuses on new launch in China - The Pharma Letter","headline":"UCB closes portfolio divestment and focuses on new launch in China","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgJBVV95cUxQYXlpWWtJNGNLZHJEeWRMRnR6R0E2SVY5eElibzV2ZDlyaGZ0cDNLd3Z4V2hIVWpoZlA1LUw5SEd6SHRHbWNva1VQcUExU1FQN1lWV3pBN2M4aUktay16cGpCc2pPc2xsOWlwUzBvMXFGbmduaG5OdE1mZEM5aEdlN3BsNU1LNER4eWtScEpHb1hKUllUWm1OSndEM3MySmF6d3VPY0Q5ZVFjclBWUG5TMGNpODhhYWdiUlFQbV94T0g1T3RyZ2FnOWlhS0Z1c0xpNnExUGJBMTJfSGNGR01paGlveU5mazNqMV9JM1FIX1FlSzUwSjJ4VEtBWjVtWTVfTmpteW9n?oc=5","date":"2024-11-19","type":"regulatory","source":"PR Newswire","summary":"Systemic Lupus Erythematosus Clinical Trial Pipeline Gains Momentum as 120+ Key Companies at the Forefront | DelveInsight - PR Newswire","headline":"Systemic Lupus Erythematosus Clinical Trial Pipeline Gains Momentum as 120+ Key Companies at the Forefront | DelveInsigh","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxPeWJsbW9iS3dtbndzR19JbTByN096a3hxaV90SUxMTTNLM2F4d0RyakI5Mlk0YTB3V1RTdHdyWDdsOU9ValpFVFpJZ01qRFdVNUNtNWltc3BRc01lRi1sZjRtSTlzdm9wcEwtZ1Rsa1RRZnlEOFUyRmEtb04zd0dsZmpuRTR1U1hCNUpfY0xid1B5aG91Y3hiUFJBZHF2a2dJQjhuMzdOWFYzcUc4TVcwOFRJNmdzY09CN1ZGcDNoSks?oc=5","date":"2023-09-14","type":"regulatory","source":"BioPharma APAC","summary":"BioRay's Zuberitamab (Anruixi®) First Domestic Anti-CD20 Antibody Approved in China - BioPharma APAC","headline":"BioRay's Zuberitamab (Anruixi®) First Domestic Anti-CD20 Antibody Approved in China","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxQRGowd0t1WHN4X2p5MmdfWU1ET01VdDBRdkVCZkFjTmxTeklFbTN0bWZYMTlUeVhYSXUxTnRGeFdnOV9VZUtkSnVCRjJ6RTlJWHpiakpwVjV5MGJvWGhBWXc5V292dUZFNUxlMjZ6SF9BZmNTOEllQkZvTlYyOFJwMmdpSFhFR2RKN3RaV2VMcno4TTRMS09WYkQwUng?oc=5","date":"2023-07-26","type":"pipeline","source":"CRISPR Medicine News","summary":"Clinical Roundup: Gene-Edited Therapies for Beta Thalassemia - CRISPR Medicine News","headline":"Clinical Roundup: Gene-Edited Therapies for Beta Thalassemia","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidkFVX3lxTE1RTTE0bWJQNU8yQ0tRYTh6NUFBcHNYMmNiT2M1VTNoQWRnbE14QWNoWHpxczYzUlIxUmxDQ2NaXzNNMkl5YWp2SWh5WWhySWg3VzJVOVRpRXdObGJsZndIZlNxQU81Vk1CRFl5dVhaa0liNzRFeEE?oc=5","date":"2023-02-06","type":"pipeline","source":"Labiotech.eu","summary":"The biggest private biotech investments in January 2023 - Labiotech.eu","headline":"The biggest private biotech investments in January 2023","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxQdkpUc2xITkplR3A0TWtIVTFnZlBFeUhGOFJtMzBra0FURjBmME1DVVFFWEpVUTBwX195NHhjNzc2ckU5czdTTTU3M3poLW1PWHpFaHEzLU43ZUtWQ1BuT01YUG1QWWlXVFRod2tPRlBpVExaZkRkbjg5dHp0RldiLTNBWUdlMVFvR0h4Yjl3ekNDZzl1TGRSczVnaGxsVGtWMnRESDVSWUJjU1VMM1hhMUZFS2FsazhSZzZn?oc=5","date":"2021-08-14","type":"patent","source":"Generics and Biosimilars Initiative","summary":"Huons enters biosimilar market while private equity firm PAG invests in Hisun BioRay - Generics and Biosimilars Initiative","headline":"Huons enters biosimilar market while private equity firm PAG invests in Hisun BioRay","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}